Sands Capital Ventures’s 10x Genomics TXG Stock Holding History

Sands Capital Ventures’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.5M	Hold	481,770	–	–	3.01%	11
2026 Q1	$10.2M	Hold	481,770	–	–	2.43%	10
2025 Q4	$7.86M	Hold	481,770	–	–	1.52%	13
2025 Q3	$5.63M	Hold	481,770	–	–	1.23%	15
2025 Q2	$5.58M	Hold	481,770	–	–	1.1%	14
2025 Q1	$4.21M	Hold	481,770	–	–	1.03%	14
2024 Q4	$6.92M	Hold	481,770	–	–	1.5%	13
2024 Q3	$10.9M	Hold	481,770	–	–	3.06%	8
2024 Q2	$9.37M	Hold	481,770	–	–	3.14%	7
2024 Q1	$18.1M	Hold	481,770	–	–	4.36%	6
2023 Q4	$27M	Hold	481,770	–	–	7.5%	6
2023 Q3	$19.9M	Hold	481,770	–	–	5.88%	7
2023 Q2	$26.9M	Hold	481,770	–	–	7.96%	6
2023 Q1	$26.9M	Hold	481,770	–	–	6.64%	7
2022 Q4	$17.6M	Hold	481,770	–	–	4.81%	10
2022 Q3	$13.7M	Hold	481,770	–	–	3.99%	8
2022 Q2	$21.8M	Buy	+481,770	New	+$25M	5.99%	8

Other funds holding TXG

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Sands Capital Ventures's TXG Position: Q2 2026 in Review

Sands Capital Ventures held its 10x Genomics (TXG) position steady in Q2 2026 at 481,770 shares worth $18.5M. The position accounts for 3.01% of the portfolio, ranked #11.

Sands Capital Ventures first reported a position in TXG in Q2 2022 and has held it in 17 quarters since. The position peaked at $27M in Q4 2023. 368 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Sands Capital Ventures held 481,770 shares of 10x Genomics worth $18.5M as of Q2 2026.
Sands Capital Ventures left its 10x Genomics share count unchanged in Q2 2026.
10x Genomics made up 3.01% of Sands Capital Ventures's portfolio in Q2 2026, its #11 holding.
Sands Capital Ventures first reported a position in 10x Genomics in Q2 2022 and has held it in 17 quarters since.
Sands Capital Ventures's 10x Genomics position peaked at $27M in Q4 2023.
368 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Sands Capital Ventures's 13F filing for Q2 2026, filed 13 Aug 2026.